Your browser doesn't support javascript.
loading
Bone marrow activation in response to metabolic syndrome and early atherosclerosis.
Devesa, Ana; Lobo-González, Manuel; Martínez-Milla, Juan; Oliva, Belén; García-Lunar, Inés; Mastrangelo, Annalaura; España, Samuel; Sanz, Javier; Mendiguren, José M; Bueno, Hector; Fuster, Jose J; Andrés, Vicente; Fernández-Ortiz, Antonio; Sancho, David; Fernández-Friera, Leticia; Sanchez-Gonzalez, Javier; Rossello, Xavier; Ibanez, Borja; Fuster, Valentin.
Afiliación
  • Devesa A; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Lobo-González M; Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Martínez-Milla J; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Oliva B; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • García-Lunar I; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Mastrangelo A; Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • España S; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Sanz J; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Mendiguren JM; Cardiology Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Bueno H; CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
  • Fuster JJ; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Andrés V; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Fernández-Ortiz A; Departamento de Estructura de la Materia, Física Térmica y Electrónica, Universidad Complutense de Madrid, IdISSC, Madrid, Spain.
  • Sancho D; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Fernández-Friera L; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sanchez-Gonzalez J; Banco de Santander, Madrid, Spain.
  • Rossello X; Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, Madrid 28029, Spain.
  • Ibanez B; CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
  • Fuster V; Cardiology Department, Hospital Universitario 12 de Octubre, and i+12 Research Institute, Madrid, Spain.
Eur Heart J ; 43(19): 1809-1828, 2022 05 14.
Article en En | MEDLINE | ID: mdl-35567559
AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND RESULTS: Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). CONCLUSION: In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Metabólico / Aterosclerosis / Placa Aterosclerótica Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur Heart J Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Metabólico / Aterosclerosis / Placa Aterosclerótica Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur Heart J Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido